Is Matrix Metalloproteinase-9 Associated with Post-Stroke Cognitive Impairment or Dementia?

被引:7
|
作者
Zhao, Jianhua [1 ]
Yang, Fangli [1 ]
Peng, Xue [2 ]
Li, Qing [1 ]
Wang, Fan [1 ]
Xu, Zhixiu [1 ]
Cai, Ruiyan [1 ]
Ji, Danxia [3 ]
Zhang, Jian [4 ]
Wang, Minghua [1 ]
Li, Qiong [1 ]
Ji, Sibei [1 ]
Li, Shaomin [5 ]
机构
[1] Xinxiang Med Univ, Affiliated Hosp 1, Henan Joint Int Res Lab Neurorestoratol Senile De, Henan Key Lab Neurorestoratol,Dept Neurol, Xinxiang 453100, Henan, Peoples R China
[2] Jianghan Univ, Hosp Wuhan 6, Dept Neurol, Affiliated Hosp, Wuhan 430015, Hubei, Peoples R China
[3] Xinxiang Med Univ, Dept Med Record Management, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[4] Xinxiang Med Univ, Dept Imaging, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[5] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA
关键词
ischemic stroke; post-stroke cognitive impairment or dementia (PSCID); matrix metalloprotenase 9; genetic polymorphism; cognitive function; METALLOPROTEINASE GENE POLYMORPHISMS; MATRIX METALLOPROTEINASES; HARMONIZATION STANDARDS; CEREBROSPINAL-FLUID; BRAIN; STROKE; DISEASE; INFLAMMATION; DYSFUNCTION; DISORDERS;
D O I
10.31083/j.jin2106160
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Matrix metalloproteinase-9 (MMP-9) is a significant protease required for synaptic plasticity, learning, and memory. Yet, the role of MMP-9 in the occurrence and development of cognitive decline after ischemic stroke is not fully understood. In this study, we used clinical data experiments to further investigate whether MMP-9 and genetic polymorphism are associated with poststroke cognitive impairment or dementia (PSCID). Materials and Methods: A total of 148 patients with PSCID confirmed by the Montreal Cognitive Assessment (MoCA) 3 months after onset (PSCID group) were included in the study. The MMP-9 rs3918242 polymorphisms were analyzed using polymerase chain reaction coupled with restriction fragment length polymorphism, and the serum level of MMP-9 was measured using enzyme-linked immunosorbent assay (ELISA). The same manipulations have been done on 169 ischemic stroke patients without cognitive impairment (NCI group) and 150 normal controls (NC group). Results: The expression level of serum MMP-9 in the PSCID group and NCI group was higher compared to the NC group, and the levels in the PSCID group were higher than that in the NCI group (all p < 0.05). Diabetes mellitus, hyperhomocysteinemia, and increased serum MMP-9 levels were the main risk factors of cognitive impairment after ischemic stroke. The serum level of MMP-9 was negatively correlated with the MoCA score, including visual-spatial executive, naming, attention, language, and delayed recall. Genetic polymorphism showed that TC genotype with MMP-9 rs3918242 and CC genotype were associated with a significantly increased risk of PSCID; moreover, the TC genotype significantly increased the risk of cognitive impairment. In the TCCC genotype of MMP-9 rs3918242, diabetes mellitus and hyperhomocysteinemia were associated with the increased risk of PSCID; also, hyperhomocysteinemia could increase the risk of cognitive impairment. Conclusions: MMP-9 level and MMP-9 rs3918242 polymorphism have an important role in the occurrence and development of post-stroke cognitive impairment or dementia (PSCID).
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Post-Stroke Cognitive Impairment and Dementia
    Rost, Natalia S.
    Brodtmann, Amy
    Pase, Matthew P.
    van Veluw, Susanne J.
    Biffi, Alessandro
    Duering, Marco
    Hinman, Jason D.
    Dichgans, Martin
    CIRCULATION RESEARCH, 2022, 130 (08) : 1252 - 1271
  • [2] Serum Matrix Metalloproteinase-9 and Cognitive Impairment After Acute Ischemic Stroke
    Zhong, Chongke
    Bu, Xiaoqing
    Xu, Tan
    Guo, Libing
    Wang, Xuemei
    Zhang, Jintao
    Cui, Yong
    Li, Dong
    Zhang, Jianhui
    Ju, Zhong
    Chen, Chung-Shiuan
    Chen, Jing
    Zhang, Yonghong
    He, Jiang
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (01):
  • [3] Predictive value of serum matrix metalloproteinase 9 combined with tissue inhibitor of metalloproteinase 1 for post-stroke cognitive impairment
    Pu, Mengjia
    You, Yiping
    Wang, Xuehui
    JOURNAL OF CLINICAL NEUROSCIENCE, 2022, 105 : 103 - 108
  • [4] Matrix metalloproteinase-9 increases the risk of cognitive impairment in schizophrenia
    Keshri, Neha
    Nandeesha, Hanumanthappa
    Rajappa, Medha
    Menon, Vikas
    NORDIC JOURNAL OF PSYCHIATRY, 2021, 75 (02) : 130 - 134
  • [5] Neuronal substrate of cognitive impairment in post-stroke dementia
    Deramecourt, Vincent
    Pasquier, Florence
    BRAIN, 2014, 137 : 2404 - 2405
  • [6] The role of matrix metalloproteinase-9 in dementia
    Helbecque, N
    Hermant, X
    Cottel, D
    Amouyel, P
    NEUROSCIENCE LETTERS, 2003, 350 (03) : 181 - 183
  • [7] Matrix metalloproteinase-9 polymorphism and cognitive impairment in patients with multiple sclerosis
    Zorzon, M
    Fiotti, N
    Nasuelli, D
    Altamura, N
    Bosco, A
    Giansante, C
    Zivadinov, R
    MULTIPLE SCLEROSIS, 2005, 11 : S115 - S116
  • [8] Clinical factors associated with post-stroke cognitive impairment
    Jacquin, A.
    Bejot, Y.
    Rouaud, O.
    Graule-Petot, A.
    Daubail, B.
    Osseby, G. V.
    Binquet, C.
    Giroud, M.
    CEREBROVASCULAR DISEASES, 2013, 35 : 502 - 502
  • [9] Prediabetes is associated with post-stroke cognitive impairment in ischaemic stroke patients
    Wang, Qiongzhang
    Zhao, Kai
    Cai, Yan
    Tu, Xinjie
    Liu, Yuntao
    He, Jincai
    BRAIN RESEARCH, 2018, 1687 : 137 - 143
  • [10] Post-stroke cognitive deficits and dementia
    Gallucci, Laura
    Umarova, Roza M.
    THERAPEUTISCHE UMSCHAU, 2021, 78 (06) : 305 - 311